Boston Scientific Corporation Common Stock (BSX)
Stock · NYSE · Health Care
$44.38as of 10/16/2026
Price chart
Active signals
BSX Signal Track Record
How signals performed across all stocks →What BSX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 29 | +1.4% | 55% | September 3, 2026 |
| Bollinger Band Breakout | 24 | +1.6% | 54% | August 3, 2026 |
| Bollinger Band Breakdown | 21 | +2.3% | 52% | October 7, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +0.4% | 50% | November 25, 2025 |
| Any 20-session window (baseline) | +1.3% | 58% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scop…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 59,000
Fundamentals
- 1-day range
- $43.89$44.83
- Market cap
- $71.45B
- P/E (trailing)
- 17.32
- P/E (forward)
- 13.15
- EPS (trailing)
- $2.47
- Dividend yield
- —
- Beta
- 0.59
- Avg. volume
- 19.72M
How Boston Scientific Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
29 analyst ratings
Boston Scientific Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- BSXBoston Scientific Corporation Common Stock$44.39▲ 0.57%Market cap $71.45BP/E 17.32$41.39$105.65
- MMM3M Company Common Stock$164.75▼ 0.35%Market cap $93.20BP/E 28.58$139.34$184.9
- BDXBecton Dickinson and Company Common Stock$191.75▼ 1.04%Market cap $48.79BP/E 54.13$127.59$193.07
- MDLNMedline Inc. Class A Common Stock$35.96▼ 1.67%Market cap $45.34BP/E 69.38$31.49$50.88
- RMDResMed Inc. Common Stock$238.97▼ 1.35%Market cap $32.38BP/E 22.23$180.27$277.67
- DXCMDexCom Inc. Common Stock$86.04▼ 1.90%Market cap $31.33BP/E 32.73$54.11$92.59
- WSTWest Pharmaceutical Services Inc. Common Stock$384.02▲ 0.26%Market cap $24.53BP/E 48.71$223.83$386
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BSX Boston Scientific Corporation Common Stock | $71.45B | 17.32 | $44.39 | ▲ 0.57% | $41.39$105.65 |
| MMM 3M Company Common Stock | $93.20B | 28.58 | $164.75 | ▼ 0.35% | $139.34$184.9 |
| BDX Becton Dickinson and Company Common Stock | $48.79B | 54.13 | $191.75 | ▼ 1.04% | $127.59$193.07 |
| MDLN Medline Inc. Class A Common Stock | $45.34B | 69.38 | $35.96 | ▼ 1.67% | $31.49$50.88 |
| RMD ResMed Inc. Common Stock | $32.38B | 22.23 | $238.97 | ▼ 1.35% | $180.27$277.67 |
| DXCM DexCom Inc. Common Stock | $31.33B | 32.73 | $86.04 | ▼ 1.90% | $54.11$92.59 |
| WST West Pharmaceutical Services Inc. Common Stock | $24.53B | 48.71 | $384.02 | ▲ 0.26% | $223.83$386 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51benzinga · 10/14/2026
- Why Boston Scientific (BSX) Outpaced the Stock Market TodayYahoo · 10/9/2026
- Boston sues J&J subsidiary over alleged patent infringement for cardiology deviceYahoo · 10/9/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 10/9/2026
- Boston Scientific (BSX) Advances While Market Declines: Some Information for InvestorsYahoo · 10/8/2026
- Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should KnowYahoo · 10/8/2026
- Boston Scientific names Joseph Fitzgerald as chief operating officerYahoo · 10/8/2026
- 1 Safe-and-Steady Stock to Research Further and 2 Facing ChallengesYahoo · 10/8/2026
- Why Is Boston Scientific (BSX) Reorganizing Into Three Segments Under A New COO?Yahoo · 10/8/2026
Insider Activity
Insider Actions →- Padraig Andrew O'Connor · September 2, 2026 · Option Exercise1.2K
- Padraig Andrew O'Connor · September 2, 2026 · Tax Withholding567 @ $48.37
- Susan E. Morano · August 25, 2026 · Buy2.0K @ $49.22
- Emily Woodworth · August 11, 2026 · I2.9K @ $51.19
- Jonathan Monson · August 10, 2026 · I9.9K @ $50.46
- David C. Habiger · August 5, 2026 · Buy2.1K @ $47.59
- David C. Habiger · August 4, 2026 · Buy140 @ $48.59
- Michael F. Mahoney · August 3, 2026 · I22.1K @ $48.43
- Michael F. Mahoney · August 3, 2026 · Buy186.2K @ $48.33
- David C. Habiger · August 3, 2026 · Buy1.0K @ $48.07
- Joseph Michael Fitzgerald · July 31, 2026 · I64.2K @ $46.73
- Edward J. Ludwig · July 31, 2026 · Buy5.0K @ $45.48
- Jonathan Monson · July 1, 2026 · Option Exercise2.1K
- Jonathan Monson · July 1, 2026 · Tax Withholding1.0K @ $43.06
- Michael F. Mahoney · May 28, 2026 · Gift386.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 1.29B
- Total value held
- $78.05B
- Institutional holders
- 1650
- Unknown131.82M
- Unknown96.41M
- Unknown74.23M
- Unknown67.99M
- Unknown33.29M
- Unknown32.53M
- Unknown24.43M
- Unknown22.76M
- Unknown22.27M
- Unknown19.37M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.